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Electronic Supplementary Material (ESI) for Integrative Biology. This journal is © The Royal Society of Chemistry 2018 Fig S2. Efficacy of biomaterial-based VEGF delivery does not depend on endogenous VEGF splicing. This figure is related to Fig. 2 of the main manuscript. Simulations of VEGF release from biomaterial (A), free VEGF in the PAD Calf Muscle (B), and VEGFR2 phosphorylation (C), with no endogenous secretion of VEGF 165b (0%, all VEGF 165a ), as opposed to the case shown in Fig. 2B , with all VEGF 165b (100%). All other conditions and dose size are the same as in Fig. 2B . Teal box indicates physiological range of VEGF expression, which typically varies no more than 3-5x in physiological and pathological conditions 1 . Concentration of free VEGF 165a and VEGF 165b , free antibody, and VEGF-antibody complexes in the Main Body Mass, Blood, and PAD Calf Muscle at baseline (middle) and on Day 6 following IV infusion of anti-VEGF 165b (left) or anti-VEGF (right), at different fractional VEGF 165b secretion rates in the Main Body Mass and PAD Calf Muscle. Gray arrows indicate net association of antibody and VEGF, while white arrows denote net dissociation. Note that, while at baseline only local VEGF secretion is important for signaling, upon treatment with antibody, systemic effects become important (i.e. the concentrations of VEGF 165a and VEGF 165b in the other tissue compartment affect local VEGF levels). Changes in flow directions between compartments also occur following antibody treatment. Note that VEGF 165b distribution is similarly impacted by both anti-VEGF 165b and anti-VEGF; the difference in effect arises from the concomitant redistribution of VEGF 165a by anti-VEGF. 
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Fig S9. Effects of VEGF-targeting antibodies on endothelial total VEGFR2 ligation in vivo.
This figure is related to Fig. 6 of the main manuscript. Predicted total binding of VEGF to VEGFR2 (top row), VEGF 165b -R2 (middle row), and binding of other VEGF isoforms to VEGFR2 (bottom row) in the PAD Calf Muscle at baseline (left), and fold change from baseline on Day 6 following treatment with Anti-VEGF 165b (middle) or a non-isoform-specific Anti-VEGF (right), as a function of the local fractional secretion of VEGF 165b in the PAD Calf Muscle (x-axis) and the Main Body Mass (y-axis). Black indicates an increase, while red indicates a decrease. Note differences in color scales by row. Fig S10. Effects of VEGF-targeting antibodies on endothelial cell surface VEGFR2 ligation in vivo. This figure is related to Fig. 6 of the main manuscript. Predicted total binding of VEGF to VEGFR2 (top row), VEGF 165b -R2 (middle row), and binding of other VEGF isoforms to VEGFR2 (bottom row) in the PAD Calf Muscle at baseline (left), and fold change from baseline on Day 6 following treatment with Anti-VEGF 165b (middle) or a non-isoform-specific Anti-VEGF (right), as a function of the local fractional secretion of VEGF 165b in the PAD Calf Muscle (x-axis) and the Main Body Mass (y-axis). Black indicates an increase, while red indicates a decrease. Note differences in color scales by row. Note: Changes in total other VEGF binding to VEGFR2 following anti-VEGF 165b treatment (bottom row, center) <1% (due to lack of competition between VEGF isoforms for binding to VEGFR2), which are not visible with the given scale. Middle: VEGF 165b bound to Anti-VEGF; Right: VEGF 165a bound to Anti-VEGF. Bottom: Predicted ratio of VEGF 165b to VEGF 165a bound to Anti-VEGF in the PAD Calf Muscle (left), Blood (middle), and Main Body Mass (right) at Day 6 following treatment. In most cases, VEGF 165b dominates due to its over-representation relative to its secretion fraction. Black indicates a ratio >1, while red indicates a ratio <1.
